ClinicalTrials.Veeva

Menu

MR Imaging of Perinatal Brain Injury

University of Pittsburgh logo

University of Pittsburgh

Status

Enrolling

Conditions

Perinatal White Matter Brain Injury

Treatments

Device: Magnetic Resonance Imaging
Behavioral: Neurodevelopmental Testing

Study type

Observational

Funder types

Other

Identifiers

NCT02008045
STUDY19100215

Details and patient eligibility

About

The purpose of this study is to collect and compare information from cranial ultrasounds, magnetic resonance imaging scans, neurological exam and neuropsychological assessments of children. The investigators hope that the information collected in this study will help with early screening, diagnosis and treatment of brain injury in newborns as well as identify a connection between MR imaging (MRI-magnetic resonance imaging, MRS-magnetic resonance spectroscopy) and neurodevelopmental outcome.

Full description

In the last two decades, major advances have been made in the clinical care of premature and term infants, including in the management of sepsis and respiratory compromise that can contribute to neurological disabilities in survivors. The incidence of classic cystic periventricular leukomalacia (PVL) has declined and a more diffuse and non-cystic pattern of cerebral white matter injury is more predominant. Although multiple pathologies occur in premature infants, the principal variety accounting for the predominance of neurodevelopmental disability is PVL. This disability in very low birth weight infants (VLBW) (< 1500 grams) includes cognitive/behavioral deficits in 25-50% and cerebral palsy in 5-10%. Neuroimaging studies of VLBW survivors suggest that the cerebral palsy is related to the focal necrotic lesions of PVL, whereas the cognitive/behavioral deficits correlate with more diffuse cerebral white matter injury. PVL is defined as damaged immature cerebral white matter with periventricular focal necrosis ("focal" component) in association with diffuse reactive gliosis and microglial activation in the surrounding white matter ("diffuse" component). Of note, PVL occurs in the late preterm infant and the term infant, particularly in cases of congenital heart disease. The pathogenesis of perinatal white matter injury is currently thought to be related to a complex interaction between maternal/fetal infection, cytokines and hypoxia-ischemia which results in both the generation of reactive oxygen specific agents (oxidative stress), apoptotic oligodendrocyte cell death, and axonal injury. In long-term survivors with PVL, neuroimaging studies often demonstrate reduced cerebral white matter volume, impaired myelination, ventriculomegaly and reduced volume in the cerebral cortex, thalamus/basal ganglia and cerebellum. In many of these long-term studies, the preterm children studies had normal cranial ultrasound. Cranial ultrasound, however, is not adequate for assessing non-cystic focal or diffuse white matter injury. To date, there are no longitudinal MR studies of preterm or congenital heart disease infants which correlate advanced neonatal MR imaging techniques with long-term neurodevelopmental outcome or advanced MR techniques performed in the childhood period.

Enrollment

300 estimated patients

Sex

All

Ages

1 day to 7 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Preterm babies and neonates with congenital heart disease
  • Term Neonates

Exclusion criteria

  • Severe congenital brain malformation
  • Significant chromosomal abnormality / syndrome which could confound the neurodevelopmental follow up data
  • Preterm birth and congenital heart disease
  • Focal neurological abnormality
  • Chronic seizures
  • Severe congenital brain malformation
  • Significant chromosomal abnormality/ syndrome which could confound the neurodevelopmental follow up data
  • Major pregnancy complication (diabetes, eclampsia)
  • Sepsis
  • ECMO
  • Significant birth trauma and/or hypoxic ischemic injury

Trial design

300 participants in 2 patient groups

Neonates at Risk for Brian Injury
Description:
Magnetic Resonance Imaging Neurodevelopmental Testing - 18 Month
Treatment:
Behavioral: Neurodevelopmental Testing
Device: Magnetic Resonance Imaging
Term Neonates
Description:
Magnetic Resonance Imaging Neurodevelopmental Testing - 18 Month
Treatment:
Behavioral: Neurodevelopmental Testing
Device: Magnetic Resonance Imaging

Trial contacts and locations

1

Loading...

Central trial contact

Christine P Johnson; Nancy H Beluk, RT

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems